Background: Kallikrein-1 (KLK1) is a highly conserved serine protease that is expressed in the kidney and involved in blood pressure regulation. The activity of this enzyme is diminished in acute kidney injury (AKI). Methods: We first evaluated the potential role of functional multiallelic KLK1 promoter gene polymorphisms in a case-control study of 481 subjects (214 hospitalized patients with AKI of mixed causes and 267 healthy subjects). The complex, multiallelic G/C-rich repeat region of the proximal KLK1 promoter was determined by direct Sanger/capillary resequencing. Results: 16 alleles were identified in a complex, polymorphic G/C-rich region of the KLK1 proximal promoter; 5 of these alleles (F, G, H, I, and K) were associated with development of AKI. Alleles I and G were classified as risk-alleles (unadjusted OR 1.86; 95% CI 1.23, 2.81; p = 0.003), whereas alleles F, H, and K were classified as protective-alleles (unadjusted OR 0.32; 95% CI 0.22, 0.46; p < 0.001) according to their directional association with development of AKI. After adjustment for sex, race, preexisting chronic kidney disease and APACHE II score, the KLK1 risk-allele (I or G) carrier state was associated with the composite of ≥2-fold increase in serum creatinine, oliguria, or dialysis requirement (adjusted OR 2.71; 95% CI 1.14, 6.44; p = 0.02). The KLK1 risk-allele carrier state was also marginally associated with the composite of ≥2-fold increase in serum creatinine, oliguria, dialysis requirement, or in-hospital death (adjusted OR 2.33; 95% CI 0.98, 5.52; p = 0.06). Conclusions:KLK1 promoter polymorphisms are associated with development of AKI and adverse outcomes. Further studies are needed to validate these findings.

1.
Hsu CY, McCulloch CE, Fan D, Ordonez JD, Chertow GM, Go AS: Community-based incidence of acute renal failure. Kidney Int 2007;72:208-212.
2.
Hospitalization discharge diagnoses for kidney disease - United States, 1980-2005. MMWR Morb Mortal Wkly Rep 2008;57:309-312.
3.
Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009;302:1179-1185.
4.
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:961-973.
5.
Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, Allgren RL: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000;36:767-774.
6.
Friedrich JO, Adhikari N, Herridge MS, Beyene J: Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-524.
7.
Jaber BL, Pereira BJ, Bonventre JV, Balakrishnan VS: Polymorphism of host response genes: implications in the pathogenesis and treatment of acute renal failure. Kidney Int 2005;67:14-33.
8.
Haase-Fielitz A, Haase M, Bellomo R, Dragun D: Genetic polymorphisms in sepsis- and cardiopulmonary bypass-associated acute kidney injury. Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 75-91.
9.
Haase-Fielitz A, Haase M, Bellomo R, Lambert G, Matalanis G, Story D, Doolan L, Buxton B, Gutteridge G, Luft FC, et al: Decreased catecholamine degradation associates with shock and kidney injury after cardiac surgery. J Am Soc Nephrol 2009;20:1393-1403.
10.
Alam A, O'Connor DT, Perianayagam MC, Kolyada AY, Chen Y, Rao F, Mahata M, Mahata S, Liangos O, Jaber BL: Phenylethanolamine N-methyltransferase gene polymorphisms and adverse outcomes in acute kidney injury. Nephron Clin Pract 2010;114:c253-c259.
11.
Perianayagam MC, Liangos O, Kolyada AY, Wald R, MacKinnon RW, Li L, Rao M, Balakrishnan VS, Bonventre JV, Pereira BJ, et al: NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 2007;18:255-263.
12.
Kolyada AY, Tighiouart H, Perianayagam MC, Liangos O, Madias NE, Jaber BL: A genetic variant of hypoxia-inducible factor-1α is associated with adverse outcomes in acute kidney injury. Kidney Int 2009;75:1322-1329.
13.
Jaber BL, Rao M, Guo D, Balakrishnan VS, Perianayagam MC, Freeman RB, Pereira BJ: Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine 2004;25:212-219.
14.
Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
15.
Song CK, Martinez JA, Kailasam MT, Dao TT, Wong CM, Parmer RJ, O'Connor DT: Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension. J Hum Hypertens 2000;14:461-468.
16.
Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, Bruneval P, Marre M, Alhenc-Gelas F, Bouby N: Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009;76:395-403.
17.
Ardiles LG, Figueroa CD, Mezzano SA: Renal kallikrein-kinin system damage and salt sensitivity: insights from experimental models. Kidney Int Suppl 2003;86:S2-S8.
18.
Higa EM, Schor N, Boim MA, Ajzen H, Ramos OL: Role of the prostaglandin and kallikrein-kinin systems in aminoglycoside-induced acute renal failure. Braz J Med Biol Res 1985;18:355-365.
19.
Chao J, Zhang JJ, Lin KF, Chao L: Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998;54:1250-1260.
20.
Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, Chao J: Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 2006;21:624-633.
21.
Bledsoe G, Shen B, Yao YY, Hagiwara M, Mizell B, Teuton M, Grass D, Chao L, Chao J: Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. Toxicol Sci 2008;102:433-443.
22.
Kang SW, Shih PA, Mathew RO, Mahata M, Biswas N, Rao F, Yan L, Bouchard J, Malhotra R, Tolwani A, et al: Renal kallikrein excretion and epigenetics in human acute kidney injury: expression, mechanisms and consequences. BMC Nephrol 2011;12:27.
23.
Song Q, Chao J, Chao L: DNA polymorphisms in the 5′-flanking region of the human tissue kallikrein gene. Hum Genet 1997;99:727-734.
24.
Lee-Chen GJ, Liu KP, Lai YC, Juang HS, Huang SY, Lin CY: Significance of the tissue kallikrein promoter and transforming growth factor-β1 polymorphisms with renal progression in children with vesicoureteral reflux. Kidney Int 2004;65:1467-1472.
25.
Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, Bowden DW: Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 2002;61:1030-1039.
26.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
27.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
28.
Knaus WA, Wagner DP: Multiple systems organ failure: epidemiology and prognosis. Crit Care Clin 1989;5:221-232.
29.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
30.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
31.
Zhang L, Rao F, Wessel J, Kennedy BP, Rana BK, Taupenot L, Lillie EO, Cockburn M, Schork NJ, Ziegler MG, et al: Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics 2004;19:277-291.
32.
O'Connor DT, Barg AP, Amend W, Vincenti F: Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function. Am J Med 1982;73:475-481.
33.
Funaki N, Kuroda M, Sudo J, Takeda R: Urinary prostaglandins and kallikrein in the course of acute renal failure. Prostaglandins Leukot Med 1982;9:387-399.
34.
Basile DP, Fredrich K, Alausa M, Vio CP, Liang M, Rieder MR, Greene AS, Cowley AW Jr: Identification of persistently altered gene expression in the kidney after functional recovery from ischemic acute renal failure. Am J Physiol Renal Physiol 2005;288:F953-F963.
35.
Hagiwara M, Shen B, Chao L, Chao J: Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther 2008,19:807-819.
36.
Tu L, Xu X, Wan H, Zhou C, Deng J, Xu G, Xiao X, Chen Y, Edin ML, Voltz JW, et al: Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 2008;19:318-330.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.